Cancer Cachexia Market Share Reach USD 3.43 Billion by 2032, Sustaining a Robust CAGR of 4.2% by 2032

𝐆𝐥𝐨𝐛𝐚𝐥 𝐂𝐚𝐧𝐜𝐞𝐫 𝐂𝐚𝐜𝐡𝐞𝐱𝐢𝐚 𝐌𝐚𝐫𝐤𝐞𝐭 𝐬𝐢𝐳𝐞 𝐚𝐧𝐝 𝐬𝐡𝐚𝐫𝐞 𝐢𝐬 𝐜𝐮𝐫𝐫𝐞𝐧𝐭𝐥𝐲 𝐯𝐚𝐥𝐮𝐞𝐝 𝐚𝐭 𝐔𝐒𝐃 𝟐.𝟒𝟏 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 𝟐𝟎𝟐𝟑 𝐚𝐧𝐝 𝐢𝐬 𝐚𝐧𝐭𝐢𝐜𝐢𝐩𝐚𝐭𝐞𝐝 𝐭𝐨 𝐠𝐞𝐧𝐞𝐫𝐚𝐭𝐞 𝐚𝐧 𝐞𝐬𝐭𝐢𝐦𝐚𝐭𝐞𝐝 𝐫𝐞𝐯𝐞𝐧𝐮𝐞 𝐨𝐟 𝐔𝐒𝐃 𝟑.𝟒𝟑 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 𝟐𝟎𝟑𝟐, 𝐚𝐜𝐜𝐨𝐫𝐝𝐢𝐧𝐠 𝐭𝐨 𝐭𝐡𝐞 𝐥𝐚𝐭𝐞𝐬𝐭 𝐬𝐭𝐮𝐝𝐲 𝐛𝐲 𝐏𝐨𝐥𝐚𝐫𝐢𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡. 𝐁𝐞𝐬𝐢𝐝𝐞𝐬, 𝐭𝐡𝐞 𝐫𝐞𝐩𝐨𝐫𝐭 𝐧𝐨𝐭𝐞𝐬 𝐭𝐡𝐚𝐭 𝐭𝐡𝐞 𝐦𝐚𝐫𝐤𝐞𝐭 𝐞𝐱𝐡𝐢𝐛𝐢𝐭𝐬 𝐚 𝐫𝐨𝐛𝐮𝐬𝐭 𝟒.𝟐% 𝐂𝐨𝐦𝐩𝐨𝐮𝐧𝐝 𝐀𝐧𝐧𝐮𝐚𝐥 𝐆𝐫𝐨𝐰𝐭𝐡 𝐑𝐚𝐭𝐞 (𝐂𝐀𝐆𝐑) 𝐨𝐯𝐞𝐫 𝐭𝐡𝐞 𝐟𝐨𝐫𝐞𝐜𝐚𝐬𝐭𝐞𝐝 𝐭𝐢𝐦𝐞𝐟𝐫𝐚𝐦𝐞, 𝟐𝟎𝟐𝟒 - 𝟐𝟎𝟑𝟐

Cachexia is a multifactorial illness described by weight loss through skeletal muscle and adipose tissue deprivation, a disparity in metabolic control, and decreased food consumption. It is engendered by elements of catabolism generated by tumors in an ingrained movement as well as physiological elements such as the biased, inflammatory animation, proteolysis, autophagy, and lipolysis that might take place with gastric, pancreatic, esophageal, lung cancer, liver, and bowel cancer. It not only disparagingly impacts the standard of living of patients with cancer but also decreases the potency of anti-cancer chemotherapy.

𝐂𝐥𝐢𝐜𝐤 𝐭𝐨 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅 𝐑𝐞𝐩𝐨𝐫𝐭 𝐚𝐧𝐝 𝐃𝐫𝐢𝐯𝐞 𝐈𝐦𝐩𝐚𝐜𝐭𝐟𝐮𝐥 𝐃𝐞𝐜𝐢𝐬𝐢𝐨𝐧𝐬:
https://www.polarismarketresearch.com/industry-analysis/cancer-cachexia-market/request-for-sample

𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐒𝐧𝐚𝐩𝐬𝐡𝐨𝐭

The market needs to be more cohesive with the existence of an extensive aggregate of firms. Critical market players are funding, notably in research and development ventures. Market leaders are enumerated as follows:

• AbbVie Inc. (US)
• Actimed Therapeutics (UK)
• Aeterna Zentaris Inc. (Canada)
• ANI Pharmaceuticals Inc. (US)
• Aphios Corporation (US)
• Aveo Pharmaceuticals Inc. (US)
• Bristol-Myers Squibb Company (US)
• Helsinn Group (Switzerland)
• Hikma Pharmaceuticals PLC (UK)
• Merck & Co. Inc. (US)
• Mylan N.V. (US)
• Pfizer Inc. (US)
• TCI Peptide Therapeutics (US)
• Teva Pharmaceutical Industries Ltd. (Israel)

𝐌𝐚𝐫𝐤𝐞𝐭 𝐆𝐫𝐨𝐰𝐭𝐡 𝐅𝐚𝐜𝐭𝐨𝐫𝐬

• The speedy escalation in the pervasiveness of cancer cachexia worldwide and the sizeable escalation in maturing populations who are more vulnerable to cancer are the prominent factors pushing the market's growth.

• The rising cases of cancer cachexia among cancer patients worldwide cause increased concentration of healthcare firms and private companies towards R&D funding and advancing contemporary commodities with improved potential and features to cause market growth.

𝐆𝐞𝐭 𝐀𝐡𝐞𝐚𝐝 𝐰𝐢𝐭𝐡 𝐃𝐞𝐭𝐚𝐢𝐥𝐞𝐝 𝐑𝐞𝐠𝐢𝐨𝐧𝐚𝐥 𝐌𝐚𝐫𝐤𝐞𝐭 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬:
https://www.polarismarketresearch.com/buy/3877/2

𝐆𝐞𝐨𝐠𝐫𝐚𝐩𝐡𝐢𝐜𝐚𝐥 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞

The regions covered in the report are Europe, North America, Asia Pacific, Middle East & Africa, and Latin America. According to the study, in 2023, North America held the largest cancer cachexia market share due to the escalating pervasiveness of cancer, ongoing escalation in healthcare forecasts, and an aggregate of approving government directives targeting productive treatment alternatives. Moreover, the Asia Pacific region is anticipated to expand at the fastest rate during the research period, with an optimum compound annual growth rate.

𝐆𝐫𝐨𝐰𝐭𝐡 𝐃𝐫𝐢𝐯𝐞𝐫𝐬:

𝐏𝐫𝐞𝐯𝐚𝐥𝐞𝐧𝐜𝐞 𝐨𝐟 𝐂𝐚𝐧𝐜𝐞𝐫 𝐂𝐚𝐜𝐡𝐞𝐱𝐢𝐚: The increasing prevalence of cancer worldwide contributes to the growing burden of cancer cachexia, particularly in patients with advanced or metastatic disease. Cachexia affects up to 80% of advanced cancer patients and is associated with poorer treatment outcomes, reduced quality of life, and increased mortality rates.

𝐔𝐧𝐦𝐞𝐭 𝐌𝐞𝐝𝐢𝐜𝐚𝐥 𝐍𝐞𝐞𝐝: Despite its significant impact on patient morbidity and mortality, cancer cachexia remains underrecognized and undertreated in clinical practice. There is a growing recognition of the need for effective interventions to address cachexia-related symptoms, improve nutritional status, and enhance overall patient well-being.

𝐀𝐝𝐯𝐚𝐧𝐜𝐞𝐦𝐞𝐧𝐭𝐬 𝐢𝐧 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡: Ongoing research into the pathophysiology of cancer cachexia and potential therapeutic targets has led to the identification of novel treatment strategies and drug candidates. Targeted therapies, immunomodulatory agents, and metabolic interventions are being investigated for their potential to mitigate cachexia-associated muscle wasting and metabolic disturbances.

𝐁𝐫𝐨𝐰𝐬𝐞 𝐌𝐨𝐫𝐞 𝐃𝐞𝐭𝐚𝐢𝐥𝐬:
https://www.polarismarketresearch.com/buy/3877/2

𝐌𝐚𝐫𝐤𝐞𝐭 𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧

𝐁𝐲 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬
• Progestogens
• Corticosteroids
• Combination Therapy
• Others

𝐁𝐲 𝐌𝐞𝐜𝐡𝐚𝐧𝐢𝐬𝐦 𝐨𝐟 𝐀𝐜𝐭𝐢𝐨𝐧
• Appetite Stimulators
• Weight Loss Stabilizers

𝐁𝐲 𝐃𝐢𝐬𝐭𝐫𝐢𝐛𝐮𝐭𝐢𝐨𝐧 𝐂𝐡𝐚𝐧𝐧𝐞𝐥
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

𝐂𝐚𝐧𝐜𝐞𝐫 𝐂𝐚𝐜𝐡𝐞𝐱𝐢𝐚 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬

• The Progestogens segment accounted for a notable share in 2023, on account of its greater efficiency in treatment and the presence of anti-inflammatory properties.

• Appetite stimulators segment held the majority share in 2023, which is attributed to its widespread adoption by cancer patients for maintaining body shape and mass.

• The online pharmacy segment categorized under the distribution channel is predicted to grow at the highest CAGR during the forecast period due to the growing popularity of online pharmacies due to its features like prescription management and time-saving.

• North America dominated the global market, owing to the presence of well-established healthcare infrastructure and the significant prevalence of cancer.

𝐌𝐨𝐫𝐞 𝐓𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐋𝐚𝐭𝐞𝐬𝐭 𝐑𝐞𝐩𝐨𝐫𝐭𝐬 𝐛𝐲 𝐏𝐨𝐥𝐚𝐫𝐢𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡:

𝐄𝐫𝐞𝐜𝐭𝐢𝐥𝐞 𝐃𝐲𝐬𝐟𝐮𝐧𝐜𝐭𝐢𝐨𝐧 𝐃𝐫𝐮𝐠𝐬 𝐌𝐚𝐫𝐤𝐞𝐭: https://www.polarismarketresearch.com/industry-analysis/erectile-dysfunction-drugs-market

𝐀𝐮𝐭𝐨𝐢𝐦𝐦𝐮𝐧𝐞 𝐃𝐢𝐬𝐞𝐚𝐬𝐞 𝐃𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭: https://www.polarismarketresearch.com/industry-analysis/global-autoimmune-disease-diagnostics-market

𝐃𝐢𝐚𝐛𝐞𝐭𝐞𝐬 𝐃𝐞𝐯𝐢𝐜𝐞 𝐌𝐚𝐫𝐤𝐞𝐭: https://www.polarismarketresearch.com/industry-analysis/global-diabetes-device-market

𝐏𝐫𝐞𝐟𝐢𝐥𝐥𝐞𝐝 𝐒𝐲𝐫𝐢𝐧𝐠𝐞𝐬 𝐌𝐚𝐫𝐤𝐞𝐭: https://www.polarismarketresearch.com/industry-analysis/prefilled-syringes-market

𝐂𝐨𝐧𝐭𝐚𝐜𝐭 𝐔𝐬:

Polaris Market Research
Phone: +1-929-297-9727
Email: sales@polarismarketresearch.com

𝐀𝐛𝐨𝐮𝐭 𝐔𝐬:

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR's clientele spread across different enterprises. We at Polaris are obliged to serve PMR's diverse customer base present across the industries of healthcare, technology, semiconductors, and chemicals among various other industries present around the world. We strive to provide PMR's customers with updated information on innovative technologies, high-growth markets, emerging business environments, and the latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced, and extremely qualified team of experts comprising SMEs, analysts, and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR's customers.

This release was published on openPR.